Restructuring Expenses

6 Months Ended

Jun. 30, 2020

Restructuring and Related Activities [Abstract]

Restructuring Expenses

Restructuring ExpensesIn the first quarter of 2020, the Company announced a company-wide organizational realignment initiative in order to more effectively align its organizational infrastructure and operations with the strategic vision of the autonomous pharmacy. In the second quarter of 2020, the Company continued its organizational realignment initiative, as well as initiated a restructuring plan to help mitigate the adverse impact of the COVID-19 pandemic on its business and financial results. During the three and six months ended June 30, 2020, the Company incurred and accrued $6.4 million and $10.0 million, respectively, of employee severance costs and related expenses. As of June 30, 2020, the unpaid balance related to this restructuring plan was $6.6 million.

The following table summarizes the total restructuring expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2020:

	Three Months Ended June 30, 2020		Six Months Ended June 30, 2020
	(In thousands)
Cost of product and service revenues	$	2,489	$	2,564
Research and development	2,918		3,716
Selling, general, and administrative	949		3,681
Total restructuring expense	$	6,356	$	9,961